Sinclair IS Pharma joins forces with Biocodex to crack new markets
Sinclair IS Pharma has signed a 10-year deal with Biocodex to expand its dermatology portfolio in Russia, Turkey and Europe's Benelux countries.
Sinclair IS Pharma has signed a 10-year deal with Biocodex to expand its dermatology portfolio in Russia, Turkey and Europe's Benelux countries.
Biocodex, an independent French pharmaceutical company, will support in the importation and distribution of Sinclair products to wholesalers. The company will also facilitate in marketing, advertising, and promotion of commodities to clinicians and pharmacies.
Sinclair - a London-based pharmaceutical firm focused on treatments in dermatology, wound care and oncology support - expects the new partnership will help the organisation crack new markets.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"This partnership with Biocodex supports our growth strategy to create relationships with strong strategic partners and move our product portfolio into fast-growing, emerging markets" Chris Spooner, Chief Executive Officer of Sinclair, said.
"We already have a successful distribution partnership with Biocodex in Turkey, which provides the foundation for this new multi-product, multi-country arrangement."
Sinclair products which are part of the agreement include: Kelo-cote silicone-gel scar reduction range; Sculptra collagen stimulator for deep tissue regeneration; Papulex for acne; Bio-Taches for hyperpigmentation disorders; Atopiclair for atopic dermatitis; and Sebclair for the treatment of seborrhoeic dermatitis.
RD
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
-
Is property investment still as safe as houses? Why golden era could be over
The golden era of property is over and investors are better off in the stock market, new research suggests
-
What Santander’s takeover of TSB means for customers
Santander is set to buy rival TSB for £2.65 billion. What does it mean for customers, and could we see the TSB brand disappear from the high street?